These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 19771798)

  • 1. [Erectile dysfunction as a harbinger of cardiovascular events. Long-term vascular protection with telmisartan].
    Arnheim K
    MMW Fortschr Med; 2009 Aug; 151(34-35):62-3. PubMed ID: 19771798
    [No Abstract]   [Full Text] [Related]  

  • 2. [Positive added effect of telmisartan. New therapy alternative for a large collection of cardiovascular risk patients].
    MMW Fortschr Med; 2010 Feb; 152(8):48-9. PubMed ID: 20358766
    [No Abstract]   [Full Text] [Related]  

  • 3. ONTARGET proves telmisartan efficacy compared to ramipril in cardiovascular protection of patients at high risk and without heart failure.
    Cardiovasc J Afr; 2008; 19(2):108-9; discussion 109-10. PubMed ID: 18516357
    [No Abstract]   [Full Text] [Related]  

  • 4. Does the angiotensin receptor blocker telmisartan prevent morbid atherosclerotic events?
    Cohn JN
    Nat Clin Pract Cardiovasc Med; 2008 Sep; 5(9):526-7. PubMed ID: 18665135
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Treatment of patients at high cardiovascular risk: confirmation and surprising results of the ONTARGET-Study].
    Burnier M; Waeber B; Hess O; Lüscher T
    Praxis (Bern 1994); 2008 May; 97(10):559-62. PubMed ID: 18595371
    [No Abstract]   [Full Text] [Related]  

  • 6. Telmisartan in high-risk patients intolerant of ACE inhibitors.
    Link A; Reil JC; Selejan S
    Lancet; 2009 Feb; 373(9662):458; author reply 459. PubMed ID: 19200909
    [No Abstract]   [Full Text] [Related]  

  • 7. Telmisartan in high-risk cardiovascular patients.
    Weber MA
    Am J Cardiol; 2010 Jan; 105(1 Suppl):36A-43A. PubMed ID: 20102972
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Telmisartan prevents cardiovascular events in a broad group of at-risk patients.
    Baumhäkel M; Böhm M
    Expert Opin Pharmacother; 2009 Dec; 10(18):3113-7. PubMed ID: 19925045
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [What is better here: ACE inhibitor or AT1 blocker?].
    MMW Fortschr Med; 2008 Apr; 150(16):16-7. PubMed ID: 18557213
    [No Abstract]   [Full Text] [Related]  

  • 10. Efficacy of renin-angiotensin system (RAS) blockers on cardiovascular and renal outcomes in patients with type 2 diabetes.
    Cao Z; Cooper ME
    Acta Diabetol; 2012 Aug; 49(4):243-54. PubMed ID: 21947383
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ARBs for cardiovascular and renal protection in high-risk patients.
    Aalbers J
    Cardiovasc J Afr; 2011; 22(4):224. PubMed ID: 21881697
    [No Abstract]   [Full Text] [Related]  

  • 12. Nifedipine and telmisartan for the treatment of hypertension: the TALENT study.
    Derosa G; Maffioli P
    Expert Rev Cardiovasc Ther; 2011 Dec; 9(12):1499-503. PubMed ID: 22103868
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Telmisartan is a promising cardiometabolic sartan due to its unique PPAR-gamma-inducing property.
    Yamagishi S; Takeuchi M
    Med Hypotheses; 2005; 64(3):476-8. PubMed ID: 15617852
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [In the framework of the 72nd Annual Meeting of the DKG (German CardiologySociety) in Mannheim presented: Ontarget-the until now largest study program on cardiovascular prevention in patients with hypertension].
    MMW Fortschr Med; 2006 Jun; 148(26):50-1. PubMed ID: 16875381
    [No Abstract]   [Full Text] [Related]  

  • 15. A new dawn in cardiovascular protection: total cardiovascular risk: rigorous treatment of risk factors. Introduction.
    Ritz E; Dahlöf B
    Nat Clin Pract Cardiovasc Med; 2008 Jul; 5 Suppl 1():S1-2. PubMed ID: 18580859
    [No Abstract]   [Full Text] [Related]  

  • 16. Telmisartan for the reduction of cardiovascular morbidity and mortality.
    Verdecchia P; Angeli F; Gentile G; Mazzotta G; Reboldi G
    Expert Rev Clin Pharmacol; 2011 Mar; 4(2):151-61. PubMed ID: 22115399
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The ONTARGET/TRANSCEND Trial Programme: baseline data.
    Sleight P
    Acta Diabetol; 2005 Apr; 42 Suppl 1():S50-6. PubMed ID: 15868120
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Therapy of hypertension with expanded outlook. Constant pressure decline and organ protection].
    MMW Fortschr Med; 2007 Dec; 149(49-50):52-3. PubMed ID: 18236984
    [No Abstract]   [Full Text] [Related]  

  • 19. Renin-angiotensin system blockade and cardiovascular and renal protection.
    Hoogwerf BJ
    Am J Cardiol; 2010 Jan; 105(1 Suppl):30A-5A. PubMed ID: 20102971
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypertension treatment and implications of recent cardiovascular outcome trials.
    Weber MA
    J Hypertens Suppl; 2006 Apr; 24(2):S37-44. PubMed ID: 16601560
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.